Xetra
18.11.25 | 17:35
144,65 Euro
+0,38 % +0,55
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 145,80 | 146,05 | 18.11. | |
| 145,35 | 146,20 | 18.11. |
► 18.11.: | | | | | | | | |
► 17.11.: | | | | | | | | |
► Aktueller BIOGEN Börsenkurs + Xetra-Orderbuch
► 17.11.: | | | | | | | | |
► Aktueller BIOGEN Börsenkurs + Xetra-Orderbuch
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/idp.htm [/URL] | ||||
| 352 | 144,65 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 352 | 1 | 0 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:35:52 | 144,65 | 8 |
| 16:19:45 | 143,10 | 20 |
| 16:19:27 | 143,10 | 5 |
| 16:19:27 | 143,10 | 25 |
| 15:45:01 | 142,45 | 5 |
| 15:45:01 | 142,45 | 50 |
| 15:45:01 | 142,45 | 33 |
| 15:45:01 | 142,45 | 5 |
| 15:45:01 | 142,45 | 50 |
| 15:45:01 | 142,45 | 33 |
| 15:33:04 | 140,75 | 20 |
| 15:30:52 | 140,65 | 95 |
| 15:30:52 | 140,65 | 120 |
| 15:30:41 | 140,55 | 8 |
| 15:30:41 | 140,55 | 75 |
| 15:30:41 | 140,55 | 96 |
| 15:30:41 | 141,40 | 21 |
| 14:27:53 | 141,15 | 1 |
| 14:19:29 | 141,25 | 10 |
| 14:19:29 | 141,25 | 100 |
| Tagesumsatz Xetra | +0,55 +0,38 % | 4.221 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | How Biogen is returning to its roots with a West Coast immunology outpost | 9 | FierceBiotech | ||
| Mo | After delay, Sandoz's biosimilar Tyruko launches in US to pressure Biogen's blockbuster MS med Tysabri | 5 | FiercePharma | ||
| Mo | Biogen, Stoke Release Final BUTTERFLY Study Data | 2 | RTTNews | ||
| Mo | Biogen Completes Acquisition of Alcyone Therapeutics | 8 | FinSMEs | ||
| BIOGEN Aktie jetzt für 0€ handeln | |||||
| Mo | Biogen Inc.: Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments | 284 | GlobeNewswire (Europe) | - Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative... ► Artikel lesen |
1 2 3 4 5 Weiter >>
294 Nachrichten in den letzten 12 Monaten
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Di | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India | GlobeNewswire (Europe) | SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| Di | XFRA HDP1: WIEDERAUFNAHME/RESUMPTION | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| Di | Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer | GlobeNewswire (Europe) | RAD 402 is a humanized IgG1 internalized by prostate cells, binding KLK3 with high affinity Tb-161 antitumor activity driven by the dual emission of beta particles and Auger electrons SYDNEY, Nov.... ► Artikel lesen | |
| Di | Hemostemix Inc.: Hemostemix to Showcase Breakthrough Wound Healing Therapy at Innovations in Wound Care Conference Florida | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a leader in regenerative medicine, will attend the Innovations in Wound Care Conference... ► Artikel lesen | |
| Di | Insmed Incorporated: European Commission Approves BRINSUPRI (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union | PR Newswire | - Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damagei -
- BRINSUPRI Is a First-in-Disease, First-in-Class DPP1... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOGEN INC finden Sie auf Wallstreet Online.